Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 125,18 € (+14,18 %). Medianen er 128,98 € (+17,65 %).
| Køb |
24 |
| Behold |
20 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Incyte presents ambitious pipeline plan and expects strong revenue growth
At the Wells Fargo Healthcare Conference, Incyte outlined a strategy to move the company away from dependence on Jakafi toward multiple franchises. Management expects double‑digit growth for the core business excluding Jakafi by 2030, with revenues of $3–4 billion and a peak pipeline revenue potential of $8–10 billion, driven by programs such as G12D, TGF‑beta‑PD‑1, INCA33989, VGA039 and povorcitinib. Key upcoming milestones include phase‑III data for G12D and TGF‑beta, FDA clarifications for INCA33989, and the targeted approval of povorcitinib in 2027. » Mere på de.investing.com
Incyte receives EU approval for Opzelura to treat moderate atopic dermatitis
The European Commission has approved Opzelura (ruxolitinib) from Incyte for topical treatment of moderate atopic dermatitis in adults when corticosteroids and calcineurin inhibitors are unsuitable or ineffective. The approval is based on phase‑3 data, notably the TRuE‑AD4 study with 241 patients, in which Opzelura showed significant improvements in EASI‑75 and IGA‑TS after eight weeks and achieved high success rates after 24 weeks of 84.3% (EASI‑75) and 70.6% (IGA‑TS). Common adverse events were upper respiratory tract infections and nasopharyngitis; serious infections, cardiovascular events, malignancies, or thromboses were not reported during the 24‑week observation period. » Mere på de.investing.com
Incyte reaches 52-week high of 119.60 USD
Incyte shares rose to a new 52-week high of 119.60 USD and gained 68.7% over the past year. Market capitalization is 23.74 billion USD, the P/E ratio is 16.68 and revenue growth over the last twelve months is 21.48%. Incyte also signed a global licensing agreement with Halozyme for subcutaneous development of INCA033989, is preparing data presentations for the ESMO Congress 2026, and received positive analyst reactions including a buy rating from H.C. Wainwright (price target 140 USD). BMO raised its price target to 112 USD after strong Opzelura revenue forecasts for Q2 2026. » Mere på de.investing.com
Incyte to present data on six oncology programs at ESMO 2026
Incyte will present data from six oncology programs at the ESMO 2026 congress, including phase‑1 results for INCB161734 (oral KRAS‑G12D inhibitor) and INCA33890 (bispecific TGFβR2×PD‑1 antibody). The company will feature four rapid oral presentations and two posters, including final survival data from the phase‑3 POD1UM‑303/InterAACT‑2 study on retifanlimab and data on INCB123667 in combination with bevacizumab. The first two agents are also being investigated in parallel phase‑3 programs as first‑line therapies for pancreatic cancer and microsatellite‑stable colorectal cancer, respectively. The announcement highlights a robust pipeline; the stock is trading near its 52‑week high, and the company is reported to have solid revenue growth and a strong balance sheet. » Mere på de.investing.com
Incyte hits 52-week high at $118.98
Incyte shares climbed to a new 52-week high of $118.98; market capitalization stands at $23.71 billion and the P/E ratio at 16.44. Over the past year the stock rose 74.24% and InvestingPro rates the company as undervalued with excellent financial health. Incyte completed the $1.25 billion acquisition of Vega Therapeutics, adding VGA039 (phase-3) to its hematology portfolio; the company also reported positive phase-1/2 data for latarcibart. Analysts reacted positively: H.C. Wainwright reiterated "Buy", Citizens left its rating at "Market Perform" and BMO Capital raised its price target to $112. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 1,37 mia. | 18,11 % |
| Bruttofortjeneste | 1,28 mia. | 18,45 % |
| Nettoresultat | -692,86 mio. | 291,69 % |
| EBITDA | -607,62 mio. | 240,66 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 22,4 mia. € |
Antal aktier | 203,83 mio. |
Højeste/laveste i 52 uger | 120,44 € - 81,07 € |
| Udbytte | Nej |
Beta | 0,78 |
P/E (PE Ratio) | 57,60 |
PEG (PEG Ratio) | -0,88 |
K/I (PB Ratio) | 4,36 |
P/S (PS Ratio) | 4,10 |
Virksomhedsprofil
Incyte Corporation er et biofarmaceutisk selskab, der fokuserer på opdagelse, udvikling og kommercialisering af patenterede lægemidler i USA og internationalt. Selskabet tilbyder JAKAFI, et lægemiddel til behandling af myelofibrose og polycythemia vera; PEMAZYRE, en fibroblastvækstfaktorreceptor-kinasehæmmer, der fungerer som onkogene drivkræfter i forskellige flydende og solide tumortyper; og ICLUSIG, en kinasehæmmer til behandling af kronisk myeloid leukæmi og Philadelphia-kromosompositiv akut lymfoblastisk leukæmi. Selskabets produkter i kliniske fase omfatter ruxolitinib, til behandling af steroidrefraktær kronisk graft-versus-host-sygdom (GVHD); itacitinib, som er i fase II/III-klinisk forsøg til behandling af naiv kronisk GVHD; og pemigatinib til behandling af blærekræft, cholangiocarcinom, myeloproliferativt syndrom og tumoragnostisk anvendelse. Derudover udvikler selskabet Parsaclisib, som er i fase II-klinisk forsøg for follikulært lymfom, marginalzonelymfom og mantlecelle-lymfom. Desuden udvikler det Retifanlimab, som er i fase II-kliniske forsøg for MSI-høj endometriecancer, Merkelcellecarcinom og analcancer samt i fase II-kliniske forsøg for patienter med ikke-småcellet lungecancer. Selskabet har samarbejdsaftaler med Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; og Nimble Therapeutics samt kliniske samarbejder med MorphoSys AG og Xencor, Inc. for at undersøge kombinationen af tafasitamab, plamotamab og lenalidomid hos patienter med recidiverende eller refraktært diffust storcellet B-cellelymfom og recidiverende eller refraktært follikulært lymfom. Selskabet blev stiftet i 1991 og har hovedkontor i Wilmington, Delaware.
| Navn | Incyte Co. |
| CEO | William J. Meury |
| Hjemsted | Wilmington,
de USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Lægemidler |
| Børsnotering | 04.11.1993 |
| Medarbejdere | 2.844 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | INCY |
London Stock Exchange | 0J9P.L |
Frankfurt | ICY.F |
Düsseldorf | ICY.DU |
Milan | 1INCY.MI |
London | 0J9P.L |
SIX | ICY.SW |
München | ICY.MU |